60 DEGREES PHARMACEUTICALS, INC. Operating Cash Flow
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Operating Cash Flow of -$4.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.23M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.74M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.69M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.11M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$6.85M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$5.65M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$4.54M.
- 60 DEGREES PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$1.01M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.97M 10-Q · filed 2026-08-14 | -$6.67M derived: sum of 3 quarters · filed 2026-08-14 | -$8.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$2.74M 10-Q · filed 2026-05-15 | -$4.43M derived: sum of 2 quarters · filed 2026-05-15 | -$6.54M derived: sum of 3 quarters · filed 2026-05-15 | -$7.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.80M derived: sum of 2 quarters · filed 2026-03-30 | -$5.25M derived: sum of 3 quarters · filed 2026-08-14 | -$6.85M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.56M derived: sum of 2 quarters · filed 2026-08-14 | -$5.16M 10-Q · filed 2025-11-13 | -$6.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.05M 10-Q · filed 2026-08-14 | -$4.69M derived: sum of 3 quarters · filed 2026-08-14 | -$6.37M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.60M 10-Q · filed 2026-05-15 | -$3.24M derived: sum of 2 quarters · filed 2026-05-15 | -$4.92M derived: sum of 3 quarters · filed 2026-05-15 | -$6.11M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.32M derived: sum of 2 quarters · filed 2026-03-30 | -$4.51M derived: sum of 3 quarters · filed 2026-03-30 | -$5.65M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.87M derived: sum of 2 quarters · filed 2025-11-13 | -$4.01M 10-Q · filed 2025-11-13 | -$4.07M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.33M 10-Q · filed 2025-08-13 | -$2.39M derived: sum of 3 quarters · filed 2025-08-13 | -$6.15M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$1.14M 10-Q · filed 2025-05-15 | -$1.20M derived: sum of 2 quarters · filed 2025-05-15 | -$4.96M derived: sum of 3 quarters · filed 2025-05-15 | -$5.27M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$63.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.82M derived: sum of 2 quarters · filed 2025-03-27 | -$4.13M derived: sum of 3 quarters · filed 2025-03-27 | -$4.54M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.07M derived: sum of 2 quarters · filed 2024-11-14 | -$4.48M 10-Q · filed 2024-11-14 | -$4.55M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$313.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$726.17K 10-Q · filed 2024-08-14 | -$792.14K derived: sum of 3 quarters · filed 2024-08-14 | -$1.10M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$412.68K 10-Q · filed 2024-05-15 | -$478.65K derived: sum of 2 quarters · filed 2024-05-15 | -$785.71K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$65.98K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$373.04K derived: sum of 2 quarters · filed 2024-04-01 | -$1.01M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$307.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$944.00K 10-Q · filed 2023-11-20 | ||
| 2022-06-30 | -$636.94K 10-Q · filed 2023-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |